Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Maxim Group Downgrades Kiora Pharmaceuticals to Hold

Maxim Group Downgrades Kiora Pharmaceuticals to Hold

Maxim Group analyst Michael Okunewitch downgrades Kiora Pharmaceuticals (NASDAQ:KPRX) from Buy to Hold.

byBenzinga Newsdesk

August 15, 2022

1 minute read

Maxim Group analyst Michael Okunewitch downgrades Kiora Pharmaceuticals (NASDAQ:KPRX) from Buy to Hold.

Morgan Stanley Maintains Equal-Weight on ViewRay, Raises Price Target to $4.5

By Benzinga Newsdesk

October 11, 11:28 AM

Morgan Stanley analyst Cecilia Furlong maintains ViewRay (NASDAQ:VRAY) with a Equal-Weight and raises the price target from $4 to $4.5.

VRAY

FDA Advisory Committee Votes Favoring Pfizer’s COVID-19 Pill Paxlovid

By Vandana Singh

March 17, 9:04 AM

The FDA’s Antimicrobial Drugs Advisory Committee voted 16-1 that available data support the safety and effectiveness of Pfizer Inc’s (NYSE:PFE) Paxlovid for…

PFE

Integrative Study Conducted By 10x Genomics Combines Single Cell, Spatial And In Situ Analyses To Investigate Tumor Invasiveness

By Benzinga Newsdesk

December 19, 10:09 AM

A team of 10x Genomics scientists conducted a comprehensive analysis of human breast tumor microenvironments using all three of its industry-leading platformsPLEASANTON, Calif., Dec. 19, 2023 /PRNewswire/ -- 10x

TXG